title: The chain of survival for ST-segment elevation myocardial infarction: insights into the Middle East.
abstract: Although coronary heart disease is the leading cause of morbidity and mortality in the Middle East (ME), not much is known about patients with ST-segment elevation myocardial infarction (STEMI) from this region. The STEMI Chain of Survival can be used to target regional improvements in patient care. We tried to adopt a modified chain of survival for STEMI to highlight the challenges and difficulties and the possible solutions to improve the STEMI care in the Middle East based on the few data available.
authors.affiliation: Department of Cardiology, Royal Hospital, Muscat, Sultanate of Oman. deebcardio@hotmail.com
authors.forename: Mohammed H
authors.initials: MH
authors.lastname: El-Deeb
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D017023:Coronary Angiography; D003906:Developing Countries; D042241:Early Diagnosis; D004562:Electrocardiography; D006297:Health Services Accessibility; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008877:Middle East; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D015425:Myocardial Reperfusion; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011785:Quality Assurance, Health Care / Q000379:methods*; D058996:Quality Improvement; D018570:Risk Assessment; D015912:Thrombolytic Therapy; D061665:Time-to-Treatment; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors